Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2019 Feb 8

PMID 30730019

Citations 5

Authors

Lixia Xu

Rama Natarajan

Zhen Chen

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Epigenetic variations have been shown to reveal vulnerability to diabetes and its complications. Although it has become clear that metabolic derangements, especially hyperglycemia, can impose a long-term metabolic memory that predisposes to diabetic complications, the underlying mechanisms remain to be understood. It has been suggested that epigenetics (e.g., histone modification, DNA methylation, and non-coding RNAs) help link metabolic disruption to aberrancies related to diabetic kidney disease (DKD). In this review, we discuss the key findings and advances made in the epigenetic risk profile of DKD and provide perspectives on the emerging topics that implicate epigenetics in DKD.

Recent Findings: Epigenetic profiles can be profoundly altered in patients with diabetes, in circulating blood cells as well as in renal tissues. These changes provide useful insight into the mechanisms of diabetic kidney injury and progressive kidney dysfunction. Increasing evidence supports the role of epigenetic regulation in DKD. More studies are needed to elucidate the mechanism and importance of epigenetic changes in the initiation and progression of DKD and to further explore their diagnostic and therapeutic potential in the clinical management of patients with diabetes who have a high risk for DKD.

Citing Articles

Vascular Regulation by Super Enhancer-Derived LINC00607.

Sriram K, Luo Y, Yuan D, Malhi N, Tapia A, Samara V Front Cardiovasc Med. 2022; 9:881916.

PMID: 35837599 PMC: 9274098. DOI: 10.3389/fcvm.2022.881916.

Epigenetic modifications in diabetes.

Kowluru R, Mohammad G Metabolism. 2021; 126:154920.

PMID: 34715117 PMC: 10277168. DOI: 10.1016/j.metabol.2021.154920.

Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease.

Lu H, Dai W, He L Diabetes Metab Syndr Obes. 2021; 14:329-344.

PMID: 33519221 PMC: 7837569. DOI: 10.2147/DMSO.S288500.

EGCG Attenuates Renal Damage via Reversing Klotho Hypermethylation in Diabetic db/db Mice and HK-2 Cells.

Yang X, Zhang B, Zhang X, Tong J, Gu Y, Guo L Oxid Med Cell Longev. 2020; 2020:6092715.

PMID: 32908633 PMC: 7474393. DOI: 10.1155/2020/6092715.

The epigenetics of diabetes, obesity, overweight and cardiovascular disease.

Smail H AIMS Genet. 2019; 6(3):36-45.

PMID: 31663031 PMC: 6803788. DOI: 10.3934/genet.2019.3.36.

References

Dewanjee S, Bhattacharjee N . MicroRNA: A new generation therapeutic target in diabetic nephropathy. Biochem Pharmacol. 2018; 155:32-47. DOI: 10.1016/j.bcp.2018.06.017. View

Schultz C, Neil H, Dalton R, Dunger D . Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care. 2000; 23(12):1811-5. DOI: 10.2337/diacare.23.12.1811. View

Wu D, Cheng Y, Huang X, Zhong M, Liu S, Hu S . Downregulation of lncRNA MALAT1 contributes to renal functional improvement after duodenal-jejunal bypass in a diabetic rat model. J Physiol Biochem. 2018; 74(3):431-439. DOI: 10.1007/s13105-018-0636-y. View

Chen Z, Miao F, Paterson A, Lachin J, Zhang L, Schones D . Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl Acad Sci U S A. 2016; 113(21):E3002-11. PMC: 4890596. DOI: 10.1073/pnas.1603712113. View

Sun J, Wang Y, Cui W, Lou Y, Sun G, Zhang D . Role of Epigenetic Histone Modifications in Diabetic Kidney Disease Involving Renal Fibrosis. J Diabetes Res. 2017; 2017:7242384. PMC: 5485509. DOI: 10.1155/2017/7242384. View

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

Wu J, Huang B, Chen H, Yin Q, Liu Y, Xiang Y . The landscape of accessible chromatin in mammalian preimplantation embryos. Nature. 2016; 534(7609):652-7. DOI: 10.1038/nature18606. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

10.

Gao J, Wang W, Wang F, Guo C . LncRNA-NR_033515 promotes proliferation, fibrogenesis and epithelial-to-mesenchymal transition by targeting miR-743b-5p in diabetic nephropathy. Biomed Pharmacother. 2018; 106:543-552. DOI: 10.1016/j.biopha.2018.06.104. View

11.

Tsukada Y, Fang J, Erdjument-Bromage H, Warren M, Borchers C, Tempst P . Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2005; 439(7078):811-6. DOI: 10.1038/nature04433. View

12.

Gautier J, Porcher R, Abi Khalil C, Bellili-Munoz N, Fetita L, Travert F . Kidney Dysfunction in Adult Offspring Exposed In Utero to Type 1 Diabetes Is Associated with Alterations in Genome-Wide DNA Methylation. PLoS One. 2015; 10(8):e0134654. PMC: 4530883. DOI: 10.1371/journal.pone.0134654. View

13.

Wing M, Devaney J, Joffe M, Xie D, Feldman H, Dominic E . DNA methylation profile associated with rapid decline in kidney function: findings from the CRIC study. Nephrol Dial Transplant. 2014; 29(4):864-72. PMC: 3967834. DOI: 10.1093/ndt/gft537. View

14.

Bonasio R, Tu S, Reinberg D . Molecular signals of epigenetic states. Science. 2010; 330(6004):612-6. PMC: 3772643. DOI: 10.1126/science.1191078. View

15.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

16.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

17.

Hovind P, Rossing P, Tarnow L, Smidt U, Parving H . Progression of diabetic nephropathy. Kidney Int. 2001; 59(2):702-9. DOI: 10.1046/j.1523-1755.2001.059002702.x. View

18.

Zhang H, Cai X, Yi B, Huang J, Wang J, Sun J . Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy. Mol Med Rep. 2014; 9(6):2138-44. PMC: 4055476. DOI: 10.3892/mmr.2014.2067. View

19.

Li A, Peng R, Sun Y, Liu H, Peng H, Zhang Z . LincRNA 1700020I14Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α signaling. Cell Death Dis. 2018; 9(5):461. PMC: 5919933. DOI: 10.1038/s41419-018-0527-8. View

20.

Jones C, Krolewski A, Rogus J, Xue J, Collins A, Warram J . Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause?. Kidney Int. 2005; 67(5):1684-91. DOI: 10.1111/j.1523-1755.2005.00265.x. View